Cost-Effectiveness Analysis Comparing Chemotherapy Regimens in the Treatment of AIDS-Related Kaposi’s Sarcoma in Brazil

REFERENCES

• International Collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Nat! Cancer Inst. 2000;92:1823–1830.
   PubMed Web of Science ®Google Scholar
• Mbulaiteye SM, Parkin DM, Rabkin CS. Epidemiology of AIDS-related malignancies: an international perspective. Hematol Oncol Clin N Am. 2003;17: 673–696.
   PubMed Web of Science ®Google Scholar
• Grulich AE, Li Y, McDonald AM, et al. Decreasing rates of Kaposi's sarcoma and non-Hodgkin's lymphoma in the era of potent combination antiretroviral therapy. AIDS. 200115: 629–633.
   Google Scholar
• Mocroft A, Kirk O, Clumeck N, et al. The changing pattern of Kaposi sarcoma in patients with HIV, 1994–2003: The EuroSIDA Study. Cancer. 2004;100(12):2644–2654.
   PubMed Web of Science ®Google Scholar
• Sitas F, Newton R. Kaposi's sarcoma in South Africa. J Nat! Cancer Inst. 2000;28:1–4.
   Google Scholar
• Wabinga HR, Parkin DM, Wabwire-Mangen F, et al. Trends in cancer incidence in Kyadondo County, Uganda, 1960–1997. Br J Cancer. 2000;82: 1585–1592.
   PubMed Web of Science ®Google Scholar
• Echimane AK, Ahnoux AA, Adoubi I, et al. Cancer incidence in Abidjan, Ivory Coast: first results from the cancer registry, 1995-1997. Cancer. 2000;89:653–663.
   PubMed Web of Science ®Google Scholar
• Bassett MT, Chokunonga E, Mauchaza B, et al. Cancer in the African population of Harare, Zimbabwe, 1990-1992. Int J Cancer. 1995;63:9–36.
   Web of Science ®Google Scholar
• Parkin DM, Wabinga H, Nambooze S, et al. AIDS-related cancers in Africa: maturation of the epidemic in Uganda. AIDS. 1999;13:2563–2570.
   PubMed Web of Science ®Google Scholar
• Teixeira PR, Vitoria MA, Barcarolo J, et al. Antiretroviral treatment in resource-poor settings: the Brazilian experi-ence. AIDS. 2004;18\(suppl 3):55–7.
   Google Scholar
• Levine AM, Tulpule A. Clinical aspects and management of AIDS-related Kaposi's sarcoma. Eur J Cancer. 200137: 1288–1295.
   PubMed Web of Science ®Google Scholar
• Von Roenn J H. Clinical presentations and standard therapy of AIDS-associated Kaposi's sarcoma. Hematol Oncol Clin N Am. 2003;17:747–762.
   PubMed Web of Science ®Google Scholar
• Krown SE. Highly active antiretroviral therapy in AIDS-asso-ciated Kaposi's sarcoma: implications for the design of therapeutic trials in patients with advanced, symptomatic Kaposi's sarcoma. J Clin Oncol. 2004;22:399–402.
   PubMed Web of Science ®Google Scholar
• Olweny CL, Borok M, Gudza I, et al. Treatment of AIDS-associated Kaposi's sarcoma in Zimbabwe: results of a randomized quality of life focused clinical trial. Int J Cancer. 2005;113:632–639.
   PubMed Web of Science ®Google Scholar
• Bennett CL, Golub RM, Stinson TJ, et al. Cost-effectiveness analysis comparing liposomal anthracyclines in the treat-ment of AIDS-related Kaposi's sarcoma. J Acquir Immune Defic Syndr. 1998;18(5):460–465.
   Web of Science ®Google Scholar
• Hjoitsberg C, Person U, Lidbrink E, et al. Cost-effectiveness analysis of pegylated-liposomal doxorubicin and liposomal daunorubicin treatments in patients with Kaposi's sarcoma. Acta Oncol. 1999;38(8):1063–1067.
   PubMed Web of Science ®Google Scholar
• Welte R, Feenstra T, Jager H. A decision chart for assessing and improving the transferability of economic evaluations results between countries. Pharmacoeconomics. 2004;22(13):857–876.
   PubMed Web of Science ®Google Scholar
• Gill PS, Wernz J, Scadden DT, et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin and vincristine in AIDS related Kaposi's sarcoma. J Clin Oncol. 1996;14:2353–2364.
   PubMed Web of Science ®Google Scholar
• Noithfelt DW, Dezube BJ, Thommes JA, et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sar-coma: results of a randomized phase III clinical trial. J Clin Oncol. 1998;16:2445–2451.
   PubMed Web of Science ®Google Scholar
• Smith TJ, Hillner BE, Desch CE. Efficacy and cost-effective-ness of cancer treatment: rational allocation of resources based on decision analysis. J Nat/ Cancer inst.1993;85: 1460–1474.
   PubMed Web of Science ®Google Scholar
• Bennett CL, Armitage JL, Buchner D, et al. Economic analy-sis in phase III clinical cancer trials. Cancer Invest. 1994;12:336–342.
   PubMed Web of Science ®Google Scholar
• Stewart JSW, Jabonowski H, Goebel FD, et al. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. J Clin Oncol. 1998;16:683–691.
   PubMed Web of Science ®Google Scholar
• Krown SE, Metroka C, Wernz JC. Kaposi's sarcoma and the acquired immunedeficiency syndrome: a proposal for a uni-form evaluation, response and staging criteria. J Clin Oncol 1989;7: 1201–1207.
   PubMed Web of Science ®Google Scholar
• Krown SE, Testa MA, Huang J, et al. AIDS-related Kaposi's sarcoma: prospective validation of the AIDS Clinical Trial Group staging classification. J Clin Oncol 1997;15:3085–3092.
   PubMed Web of Science ®Google Scholar
• Brazilian Ministry of Health - Health Prices Data Bank 2004 (Banco de Pregos em Saa - Ministério da Saale 2004). Available at: http://owssrv1.saude.gov.bribprefd/owa/consulta.inicio. Accessed September 10,2005.
   Google Scholar
• Rosenthal E, Poizot-Martin I, Saint-Marc T, et al. Phase IV study of liposomal daunorubicin (DaunoXome) in AIDS-re-lated Kaposi sarcoma. Am J Clin Oncol. 2002;25:57–59.
   PubMed Web of Science ®Google Scholar
• Martfn-Carbonero L, Barrios A, SabaIls P, et al. Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcoma. AIDS. 2004;18: 1737–1740.
   PubMed Web of Science ®Google Scholar
• Tulpule A, Yung RC, Wernz J, et al. Phase II trial of liposomal daunorubicin in the treatment of AIDS-related pulmonary Kaposi's sarcoma. J Clin Oncol. 1998;16:3369–3374.
   PubMed Web of Science ®Google Scholar
• Bower M, Fox P, Fife K, et al. Highly active antiretroviral therapy prolongs time to treatment failure in Kaposi's sar-coma. AIDS. 1999;13:2105–2111.
   PubMed Web of Science ®Google Scholar
• Leitch H, Trudeau M, Routy JP. Effect of protease inhibitor-based highly active antiretroviral therapy on survival in HIV-associated advanced Kaposi's sarcoma patients treated with chemotherapy. HIV Clin Trials. 2003;4:107–114.
   Google Scholar
• Lichterfeld M, Qurishi N, Hoffmann C, et al. Treatment of HIV-1-associated Kaposi's sarcoma with pegylated liposo-mal doxorubicin and HAART simultaneously induces effec-tive tumor remission and CD4+ T cell recovery. Infection. 2005;33:140–147.
   PubMed Web of Science ®Google Scholar
• Lynen L, Zolfo M, Huyst V, et al. Management of Kaposi's sarcoma in resource-limited setting in the era of HAART. AIDS Reviews. 2005;7:13–21.
   PubMed Web of Science ®Google Scholar
• Dedicoat M, Vaithilingum M, Newton R. Treatment of Kaposi's sarcoma in HIV-1 infected individuals with empha-sis on resource poor settings (Cochrane Review). In: The Cochrane Library, Issue 2, 2004. Oxford: Update Software.
   Google Scholar